Brokerages Set Traws Pharma, Inc. (NASDAQ:TRAW) Target Price at $1.00

Traws Pharma, Inc. (NASDAQ:TRAW) has received a consensus rating of “Reduce” from the five analysts that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $1.00.

TRAW has been the subject of several research reports. HC Wainwright restated a “negative” rating and set a $1.00 price objective on shares of Traws Pharma in a research report on Thursday, June 18th. Citigroup downgraded Traws Pharma to a “neutral” rating in a research note on Monday, June 15th. LADENBURG THALM/SH SH cut shares of Traws Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 15th. Wall Street Zen raised shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Weiss Ratings lowered shares of Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, May 29th.

Insider Activity

In related news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The shares were bought at an average price of $1.67 per share, for a total transaction of $998,207.43. Following the completion of the transaction, the insider owned 1,203,250 shares of the company’s stock, valued at approximately $2,009,427.50. This trade represents a 98.71% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 7.57% of the company’s stock.

Institutional Investors Weigh In On Traws Pharma

Large investors have recently modified their holdings of the business. State Street Corp bought a new position in Traws Pharma in the 4th quarter valued at approximately $29,000. Two Sigma Investments LP lifted its stake in shares of Traws Pharma by 37.1% in the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after acquiring an additional 5,955 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Traws Pharma by 294.2% during the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after acquiring an additional 31,502 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Traws Pharma during the 4th quarter valued at $56,000. Finally, Geode Capital Management LLC grew its position in Traws Pharma by 41.9% during the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after acquiring an additional 18,213 shares during the last quarter. Institutional investors and hedge funds own 7.95% of the company’s stock.

Traws Pharma Trading Up 2.9%

TRAW stock opened at $0.70 on Friday. The stock has a 50-day moving average price of $1.22 and a two-hundred day moving average price of $1.54. Traws Pharma has a 1 year low of $0.64 and a 1 year high of $3.27. The stock has a market cap of $10.68 million, a PE ratio of -0.42 and a beta of 1.51.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.39. On average, analysts forecast that Traws Pharma will post -1.43 earnings per share for the current fiscal year.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.